IBB241018P80000
- 0.05
- 0.000.00%
iShares Biotechnology ETF Newsroom
Scotiabank Initiates Coverage On Vertex Pharmaceuticals With Sector Perform Rating, Announces Price Target of $480
Alnylam Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Big Banks Gather Investors' Confidence
Argenx Highlights Patient Impact Data Across Immunology Programs At 2024 AANEM And MGFA Scientific Session
Trump or Harris? Analysts are hotly debating the impact of the election results on various sectors of the US stock market.
①Over the past 8 years, the Trump administration and the Biden-Harris administration have fully demonstrated their policy orientations; ②Overall, industries such as finance and technology that are under the key regulation of the Biden administration are more likely to benefit from Trump's "rollback" policies, while the bullish outlook for other industries is relatively less obvious.
Jasper Gains 11% on Data for Briquilimab in Urticaria
Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe
Vertex Pharmaceuticals Analyst Ratings
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
Redburn Atlantic Initiates Coverage On IQVIA Hldgs With Buy Rating, Announces Price Target of $276
Morgan Stanley Screens for Quality Cyclicals as Economic Surprises, Yields Back Upgrade
Eight Stocks Positioned for Short Sales – Oppenheimer Asset Management
Amgen Analyst Ratings
The bull market in US stocks will enter its third year. The three major stock index futures show mixed movements before the market opens. | Tonight's highlights
①The Nasdaq 100 index futures rose more than 0.4% in pre-market trading; ②Apple is set to launch a $2000 Vision headset as early as next year; ③Taiwan Semiconductor plans to establish more chip factories in Europe; ④GlaxoSmithKline's experimental drug for treating rhinitis has shown positive results.
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Monday Ahead of Earnings Deluge
Amgen Downgraded at Truist on MariTide Prospects for Obesity
Eli Lilly CEO Told UK Health Secretary Its Alzheimer's Treatment Could "Prevent" Disease: FT
Weight Loss Drugs Have One Big Issue; These Companies Want to Fix It
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target